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A 36-year-old male patient presented with rapidly pro-gressive dyspnea over 3 weeks. Computed tomography
scan showed a tumor in the right atrium, multiple bilateral
pulmonary nodules, and ground-glass infiltrates. Histology
obtained by wedge resection of a lung nodule revealed a
high-grade epithelial angiosarcoma. Therefore, the patient
was diagnosed with angiosarcoma from the right atrium
with multiple lung metastases. During the 2 weeks of
diagnostic workup, the dyspnea had worsened to New
York Heart Association grade IV, and a repeated computed
tomography scan showed rapidly progressing pulmonary
metastases and infiltrates (Figure 1A). The decision was
taken to quickly initiate chemotherapy with doxorubicin
(75 mg/m2) and ifosfamide (7500 mg/m2) every 3 weeks.
After two cycles of chemotherapy treatment, the patient’s
overall condition had markedly improved, and the dyspnea
was reduced to New York Heart Association grade I. A
partial remission was achieved after six cycles of combi-
nation chemotherapy (Figure 1B). Four months later, pro-
gression of the primary tumor in the right atrium was
diagnosed as well as slightly progressive pulmonary me-
tastases. To avoid the danger of complete obstruction of
the right atrium (Figure 2A), we decided to treat the patient
with a combination of radiotherapy (22 fractions of 2 Gy)
to the right atrium and weekly paclitaxel (80 mg/m2
weekly). The local response to treatment was good with a
marked reduction of the atrial tumor mass (Figure 2B). A
few months later, however, there was new evidence of
liver metastases. At that point, the patient refused any
further treatment. He died 12 months after the initial
diagnosis due to an acute intraabdominal hemorrhage
most likely deriving from the rapidly progressive liver
metastases.
DISCUSSION
Primary cardiac angiosarcoma (PCA) is an uncom-
mon diagnosis although it is the most frequent primary
malignant tumor of the heart. Seventy-five percent of PCA
occur in the right heart, especially the right atrium.1
Complete resection of localized tumors is the treatment of
choice in PCA, and there are anecdotal reports of long-
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FIGURE 1. A, Thoracic computed tomography (CT) scan
showing multiple pulmonary metastases and ground-glass
infiltrates. B, Thoracic CT scan after first-line chemotherapy
showing marked regression of pulmonary metastases and
ground-glass infiltrates. R, right; L, left.
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term survival in patients treated with surgery and adjuvant
chemotherapy and/or radiotherapy.2 However, the majority
of patients with cardiac sarcomas present with unresect-
able tumors and metastatic disease and have a poor prog-
nosis.1 Few data are available for the most appropriate
management of cardiac sarcomas.1 Doxorubicin and ifos-
famide are the two most important cytotoxic drugs used as
monotherapy in the treatment of soft tissue sarcomas. The
combination of ifosfamide and doxorubicin is associated
not only with increased response rates but also higher rates
of adverse events.3 Although the routine addition of ifos-
famide to standard first-line doxorubicin-containing re-
gimes is not recommended, it is considered reasonable to
use such combinations in patients for whom higher re-
sponse rates are necessary.3 Paclitaxel has been shown to
be effective in advanced-stage angiosarcoma and has also
been used as second-line treatment.4 Radiation to the right
atrium combined with weekly paclitaxel as treatment in
inoperable PCA has not been reported before. In a single
published case, radiotherapy with concomitant docetaxel
was associated with clinical benefit in PCA.5 Our case dem-
onstrates that cardiac angiosarcoma is sensitive to aggressive
combination chemotherapy as well as taxane-based concom-
itant chemoradiotherapy. However, advanced disease remains
fatal in most cases.
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FIGURE 2. A, Transesophageal echocardiography: tumor
(TU) infiltrating the right atrium (RA) with danger of intra-
cavital obstruction. B, Transesophageal echocardiography
after radiotherapy of the right atrium showing marked re-
gression of the tumor. VCS, vena cava superior; TV, tricuspid
valve; RV, right ventricle; LA, left atrium.
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